Biotech News
Alumis and ACELYRIN Join Forces to Drive Late-Stage Immunology Therapies
Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement under which both companies will combine in an all-stock transaction. The merger aims to enhance financial flexibility and support the advancement of a late-stage immunology pipeline. With a pro
10 February 2025